Video

Carboplatin Versus Cisplatin in Cervical Cancer

A noninferiority trial conducted by investigators from Japan, JCOG0505, evaluated cisplatin and paclitaxel compared with carboplatin and paclitaxel in 253 women with advanced or metastatic cervical cancer. Results from the intent-to-treat population showed similar survival outcomes between the two regimens, suggesting that carboplatin may be interchangeable with cisplatin (HR, 0.994; P = .032).

This was an important study that changed the standard of care, notes Angeles Alvarez Secord, MD. However, a prespecified subgroup analysis showed that individuals who were cisplatin-naïve and treated with the carboplatin-containing regimen had a worse survival outcome. In this analysis of cisplatin-naïve patients, carboplatin and paclitaxel showed an overall survival of 13 months compared with 23.2 months for those treated with cisplatin and paclitaxel (HR, 1.571).

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Related Videos
Elizabeth Lee, MD, a gynecologic oncologist and the gynecologic oncology program's liaison to the Center for Cancer Therapeutics Innovation at Dana-Farber Cancer Institute
Taliya Lantsman, MD, a hematology/oncology fellow at Beth Israel Deaconess Medical Center
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Jordyn Silverstein, MD
Rachel N. Grisham, MD
Toon Van Gorp, MD, PhD
Katherine L. Nathanson, MD
Matthew Wagar, MD of the University of Wisconsin School of Medicine and Public Health
Kathleen N. Moore, MD, MS
Dr Salani on Novel Trial Designs and Therapies in Gynecologic Malignancies